Proactive Investors
14 Jul 2026, 06:46 UTC · 1h ago
Poolbeg Pharma raises £3.5m to support key trial and GLP-1 progress
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
14 Jul 2026, 06:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Poolbeg Pharma has raised £3.5 million through a share placing to fund clinical trials and strengthen partnering discussions. — Fresh capital reduces immediate bankruptcy risk and provides the necessary runway to achieve clinical milestones.
+0.40The company's cash runway has been extended into the second quarter of 2028. — A defined runway provides market certainty regarding the company's survival and operational timeline.
+0.30Poolbeg is funding an oral GLP-1 proof-of-concept trial targeting the appetite-suppressing pathway used by drugs like Wegovy. — Entry into the high-growth GLP-1/weight-loss market creates significant potential upside if the proof-of-concept is successful.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
The funding will support the completion of the POLB 001 TOPICAL trial for preventing cytokine release syndrome. — Completion of a core pipeline trial is a critical binary event for a clinical-stage biotech company.
+0.20Which stocks this story touches
The company successfully raised £3.5 million to fund clinical trials and extend its cash runway into 2028.
Johnson & Johnson is mentioned only as a provider of a treatment in a clinical trial context.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
22h ago
